FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2065935185> ?p ?o ?g. }

• W2065935185 endingPage "1341" @default.
• W2065935185 startingPage "1337" @default.
• W2065935185 abstract "Background: In February 2003, the National Institute of Child Health and Human Development (NICHD) and the US Food and Drug Administration (FDA) created the Newborn Drug Development Initiative (NDDI), an ongoing program to determine gaps in knowledge in neonatal therapeutics and to explore clinical study designs for use in the newborn population. Working groups were established in 3 therapeutic areas: the central nervous, pulmonary, and cardiovascular systems. Three additional groups discussed pain control, drug prioritization, and ethics in neonatal clinical trials. Objective: The purpose of this article was to provide an overview of the 5 articles written by members of the Neurology, Cardiology, Drug Prioritization, and Ethics Groups. Methods: Information for the current article, as well as the 5 articles presented in this supplemental section, was gathered from the proceedings of a workshop cosponsored by the NICHD and the FDA. This workshop took place March 29 and 30, 2004, in Baltimore, Maryland. Results: The Neurology Group addressed the treatment of 2 common and interrelated conditions in the newborn population: neonatal seizures and hypoxic-ischemic encephalopathy. The unsubstantiated clinical preference for using phenobarbital to treat neonatal seizures, coupled with the development of several newer antiepileptic drugs with application in children, dictates the need for rigorous clinical trials of these drugs in the neonatal population. A number of pharmacologic agents currently undergoing extensive investigations in experimental animals and adult humans may have application in the newborn population. The Cardiology Group reviewed controversial approaches to the diagnosis and treatment of cardiovascular instability of preterm infants and identified gaps in knowledge. The group discussed issues of study design and developed 2 study proposals: (1) a placebo-controlled trial with a rescue arm for symptomatic infants; and (2) a targeted blood pressure (BP) trial. The Drug Prioritization Group focused on the fact that the uniqueness of the newborn population is due to distinctive and changing physiologic characteristics, conditions, and diseases that are different from those affecting older children, as well as the large differences in developmental patterns between 23 weeks of gestation and term. All of these factors help explain the lack of adequate trials and the sparseness of evidence regarding efficacy and toxicity risks of most drugs used in the newborn population. Unfortunately, the requency of drug use and polypharmacy is highest in very-low-birth-weight infants. The large number of drugs requiring study and the uniqueness of the indications for those drugs preclude the use of the prioritization process used in older children. The focus of the Drug Prioritization Group was the determination of factors that identify which drugs are most important for study. The Ethics Group was unique in that its members were integrated into the therapeutic groups. This approach allowed for the identification of similarities and dissimilarities in the proposed clinical trial design framework. The summary report included here identifies common themes voiced in the various NDDI reports and deliberations. Conclusions: The 5 articles included in this issue address different issues but share common themes: the need to develop innovative trial designs and biomarkers of efficacy, consideration of ethical concerns, and selection of appropriate drugs for study." @default.
• W2065935185 created "2016-06-24" @default.
• W2065935185 creator A5023758717 @default.
• W2065935185 creator A5079840412 @default.
• W2065935185 date "2006-09-01" @default.
• W2065935185 modified "2023-09-24" @default.
• W2065935185 title "Selected Proceedings of the NICHD/FDA newborn drug development initiative: Part II" @default.
• W2065935185 cites W1971176779 @default.
• W2065935185 cites W1972090907 @default.
• W2065935185 cites W1991437586 @default.
• W2065935185 cites W2008052975 @default.
• W2065935185 cites W2014030699 @default.
• W2065935185 cites W2019373852 @default.
• W2065935185 cites W2021188919 @default.
• W2065935185 cites W2040450806 @default.
• W2065935185 cites W2050218543 @default.
• W2065935185 cites W2055221148 @default.
• W2065935185 cites W2064283952 @default.
• W2065935185 cites W2115554249 @default.
• W2065935185 cites W2118155986 @default.
• W2065935185 cites W2158941494 @default.
• W2065935185 doi "https://doi.org/10.1016/j.clinthera.2006.09.003" @default.
• W2065935185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17062307" @default.
• W2065935185 hasPublicationYear "2006" @default.
• W2065935185 type Work @default.
• W2065935185 sameAs 2065935185 @default.
• W2065935185 citedByCount "3" @default.
• W2065935185 countsByYear W20659351852013 @default.
• W2065935185 countsByYear W20659351852014 @default.
• W2065935185 crossrefType "journal-article" @default.
• W2065935185 hasAuthorship W2065935185A5023758717 @default.
• W2065935185 hasAuthorship W2065935185A5079840412 @default.
• W2065935185 hasConcept C126322002 @default.
• W2065935185 hasConcept C177713679 @default.
• W2065935185 hasConcept C187212893 @default.
• W2065935185 hasConcept C2780035454 @default.
• W2065935185 hasConcept C2908647359 @default.
• W2065935185 hasConcept C535046627 @default.
• W2065935185 hasConcept C64903051 @default.
• W2065935185 hasConcept C71924100 @default.
• W2065935185 hasConcept C98274493 @default.
• W2065935185 hasConcept C99454951 @default.
• W2065935185 hasConceptScore W2065935185C126322002 @default.
• W2065935185 hasConceptScore W2065935185C177713679 @default.
• W2065935185 hasConceptScore W2065935185C187212893 @default.
• W2065935185 hasConceptScore W2065935185C2780035454 @default.
• W2065935185 hasConceptScore W2065935185C2908647359 @default.
• W2065935185 hasConceptScore W2065935185C535046627 @default.
• W2065935185 hasConceptScore W2065935185C64903051 @default.
• W2065935185 hasConceptScore W2065935185C71924100 @default.
• W2065935185 hasConceptScore W2065935185C98274493 @default.
• W2065935185 hasConceptScore W2065935185C99454951 @default.
• W2065935185 hasIssue "9" @default.
• W2065935185 hasLocation W20659351851 @default.
• W2065935185 hasLocation W20659351852 @default.
• W2065935185 hasOpenAccess W2065935185 @default.
• W2065935185 hasPrimaryLocation W20659351851 @default.
• W2065935185 hasRelatedWork W1977867207 @default.
• W2065935185 hasRelatedWork W1994858058 @default.
• W2065935185 hasRelatedWork W2050391874 @default.
• W2065935185 hasRelatedWork W2088663266 @default.
• W2065935185 hasRelatedWork W2319635624 @default.
• W2065935185 hasRelatedWork W2372770165 @default.
• W2065935185 hasRelatedWork W2388075619 @default.
• W2065935185 hasRelatedWork W3024269876 @default.
• W2065935185 hasRelatedWork W3049299998 @default.
• W2065935185 hasRelatedWork W4206732464 @default.
• W2065935185 hasVolume "28" @default.
• W2065935185 isParatext "false" @default.
• W2065935185 isRetracted "false" @default.
• W2065935185 magId "2065935185" @default.
• W2065935185 workType "article" @default.